LY86: A Potential Drug Target for Cancer (G9450)

Target Name: LY86

NCBI ID: G9450

LY86

Other Name(s): Protein MD-1 | dJ80N2.1 | MD-1 protein | Lymphocyte antigen 86 | protein MD-1 | Ly-86 | MD-1 | MMD-1 | ly-86 | MD1 | MD-1, RP105-associated | lymphocyte antigen 86 | LY86_HUMAN

LY86: A Potential Drug Target for Cancer

LY86, also known as Protein MD-1, is a protein that is expressed in various tissues throughout the body, including the brain, lungs, heart, kidneys, and gastrointestinal tract. It is a member of the myeloid-derived suppressor family of proteins, which are known for their ability to suppress the growth and activity of cancer cells.

Recent studies have identified LY86 as a potential drug target for several types of cancer, including breast, lung, and ovarian cancer. LY86 has also been shown to be involved in several cellular processes that are important for cancer development, including cell signaling, angiogenesis, and immune evasion.

One of the reasons for the potential of LY86 as a drug target is its unique structure. LY86 is a transmembrane protein that is composed of a single polypeptide chain that is expressed in various tissues throughout the body. This makes it a potential target for small molecules that can be administered directly into the cells. Additionally, LY86 has a relatively small number of potential drug targets, which can make it easier for drug developers to identify and test potential treatments.

Another reason for the potential of LY86 as a drug target is its involvement in several cellular processes that are important for cancer development. For example, LY86 has been shown to be involved in cell signaling, which is the process by which cells communicate with each other and with the surrounding environment. This involvement in cell signaling has been linked to the development of several types of cancer. Additionally, LY86 has been shown to be involved in angiogenesis, which is the process by which new blood vessels are formed to supply oxygen and nutrients to tissues. This involvement in angiogenesis has been linked to the development of many types of cancer, including breast and lung cancer.

In addition to its involvement in cell signaling and angiogenesis, LY86 has also been shown to be involved in several other cellular processes that are important for cancer development. For example, LY86 has been shown to play a role in the immune response, which is the process by which the body defends itself against foreign substances that attempt to enter the body. This involvement in the immune response has been linked to the development of several types of cancer.

Given its unique structure and involvement in several cellular processes that are important for cancer development, LY86 has potential as a drug target for several types of cancer. Future research is needed to fully understand the role of LY86 in cancer development and to identify potential treatments.

Protein Name: Lymphocyte Antigen 86

Functions: May cooperate with CD180 and TLR4 to mediate the innate immune response to bacterial lipopolysaccharide (LPS) and cytokine production. Important for efficient CD180 cell surface expression (By similarity)

The "LY86 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LY86 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets